宣布重大资产重组，南新制药再次20cm涨停！

Core Viewpoint - The significant increase in the stock price of Nanjing New Pharmaceutical Co., Ltd. is attributed to the announcement of a major asset restructuring involving the acquisition of specific assets from Future Pharmaceutical, which is expected to enhance the company's product offerings and financial performance [1][3]. Group 1: Asset Acquisition Details - Nanjing New Pharmaceutical signed an acquisition agreement to purchase specific assets from Future Pharmaceutical for no more than 480 million yuan [3]. - The asset group includes already marketed products "Multiple Trace Element Injection (I)" and "Multiple Trace Element Injection (II)", as well as the in-development "Multiple Trace Element Injection (III)" [3]. - The acquisition will not involve share issuance or constitute a related party transaction, and it will not change the company's control [3]. Group 2: Financial Performance Context - In 2021, the company reported a revenue of 685 million yuan, a decrease of 37.08% year-on-year, and a net loss of 167 million yuan, a decline of 225.50% compared to the previous year [4]. - The company has faced continuous losses since 2021, with a projected loss of 397 million yuan in 2024, attributed to industry policy changes and increased market competition [4]. - The company aims to improve its performance through this asset restructuring, which is seen as a strategic move to enhance revenue and profitability [4]. Group 3: Strategic Implications - The acquisition is expected to enrich the company's product pipeline and enhance its "whole-age health management" product matrix [5]. - The existing sales channels and academic promotion systems of Future Pharmaceutical will provide new sales opportunities for the company's products, particularly in expanding the market for pediatric anti-influenza medications [6].